

Correction: MALAT1 is Associated with Poor Response to Oxaliplatin-based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2



Peilong Li, Xin Zhang, Haiyan Wang, Lili Wang, Tong Liu, Lutao Du, Yongmei Yang, and Chuanxin Wang

In the original version of this article (1), wrong images were used in Fig. 2F (invasion of si-NC-transfected HT29OxR cells), Fig. 4C (migration of HT29 cells), and Fig. 5G (si-EZH2-transfected SW620 cells). The error occurred when the authors arranged the images for these figures. The authors regret this error.

Reference

1. Li P, Zhang X, Wang H, Wang L, Liu T, Du L, et al. MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2. *Mol Cancer Ther* 2017;16:739–51.

Published online February 5, 2021.

Mol Cancer Ther 2021;20:451

doi: 10.1158/1535-7163.MCT-20-1028

©2021 American Association for Cancer Research.